Analysts expect West Pharmaceutical Services, Inc. (NYSE:WST) to announce sales of $415.53 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for West Pharmaceutical Services’ earnings. The highest sales estimate is $418.00 million and the lowest is $411.50 million. West Pharmaceutical Services reported sales of $382.30 million during the same quarter last year, which indicates a positive year over year growth rate of 8.7%. The business is expected to issue its next quarterly earnings report on Thursday, February 15th.
On average, analysts expect that West Pharmaceutical Services will report full year sales of $415.53 million for the current financial year. For the next fiscal year, analysts expect that the firm will post sales of $1.73 billion per share, with estimates ranging from $1.71 billion to $1.74 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.14. The company had revenue of $398.20 million during the quarter, compared to the consensus estimate of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the firm earned $0.53 EPS.
In related news, CFO William J. Federici sold 21,000 shares of West Pharmaceutical Services stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $99.01, for a total transaction of $2,079,210.00. Following the completion of the transaction, the chief financial officer now directly owns 190,493 shares of the company’s stock, valued at approximately $18,860,711.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.90% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in West Pharmaceutical Services by 2.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 108,158 shares of the medical instruments supplier’s stock valued at $10,223,000 after purchasing an additional 2,427 shares during the last quarter. American Century Companies Inc. raised its stake in shares of West Pharmaceutical Services by 0.4% in the second quarter. American Century Companies Inc. now owns 701,364 shares of the medical instruments supplier’s stock worth $66,293,000 after acquiring an additional 2,605 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of West Pharmaceutical Services by 16.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 88,252 shares of the medical instruments supplier’s stock worth $8,342,000 after acquiring an additional 12,609 shares during the last quarter. Chatham Capital Group Inc. raised its stake in shares of West Pharmaceutical Services by 7.8% in the second quarter. Chatham Capital Group Inc. now owns 17,300 shares of the medical instruments supplier’s stock worth $1,635,000 after acquiring an additional 1,245 shares during the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of West Pharmaceutical Services by 149.6% in the second quarter. Prudential Financial Inc. now owns 400,270 shares of the medical instruments supplier’s stock worth $37,834,000 after acquiring an additional 239,906 shares during the last quarter. 93.25% of the stock is owned by hedge funds and other institutional investors.
West Pharmaceutical Services (NYSE WST) traded down $0.21 during trading hours on Wednesday, hitting $99.54. 393,357 shares of the stock were exchanged, compared to its average volume of 290,166. The company has a market cap of $7,406.73, a P/E ratio of 39.66, a price-to-earnings-growth ratio of 2.13 and a beta of 1.11. West Pharmaceutical Services has a one year low of $77.97 and a one year high of $103.36. The company has a quick ratio of 1.87, a current ratio of 2.59 and a debt-to-equity ratio of 0.15.
WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/23/west-pharmaceutical-services-inc-wst-expected-to-announce-quarterly-sales-of-415-53-million.html.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.